Apyx Medical Inc (APYX) News & EventsAPYXApyx Medical Inc

Company Expects Operating Expenses Below $45 Million for 2026

The company said, "The Company continues to expect operating expenses of less than $45.0 million for the year ended December 31, 2026."

AYON Reports Q2 Revenue of $13.88M, Beating Expectations

Reports Q2 revenue $13.88M, consensus $13.18M. "We are excited by the increasing demand for AYON throughout the U.S. market, which we believe reflects the successful execution of our commercial strategy. As a result, we reported 28% growth for the Surgical Aesthetics segment and expect AYON to continue to drive growth through the second half of the year," said Charlie Goodwin, President and Chief Executive Officer. "U.S. Surgeons continue to recognize the value of an all-in-one body contouring platform that brings together the technologies they rely on every day. With the recent FDA clearance of AYON's power liposuction capability, we are executing a measured rollout with key surgeons ahead of a initial commercial shipments in June. Alongside the expanding body of clinical evidence supporting Renuvion, these milestones reinforce our confidence in the long-term growth opportunity for our business."

Company Reports Q1 Revenue of $12.49M, Exceeding Expectations

Reports Q1 revenue $12.49M, consensus $10.77M. "Our first quarter results reflect continued execution against our commercial strategy, with strong revenue growth driven by adoption of AYON in the U.S., increasing demand for Renuvion internationally and an increase in handpieces worldwide," said Charlie Goodwin, President and Chief Executive Officer. "During the quarter, our team delivered on several fronts, including growing Surgical Aesthetic sales including expansion of AYON and exceeding expectations in key international markets such as South Korea. Taken together, this performance reinforces our confidence in the business and supports our decision to raise our revenue outlook for the full year 2026."